Neurent Medical
Neurent Medical is dedicated to transforming the treatment landscape for chronic inflammatory sinonasal diseases. Its flagship NEUROMARK System utilizes proprietary Impedance Controlled Radiofrequency technology to gently disrupt hyperactive posterior nasal nerves, delivering durable symptom relief from chronic rhinitis with minimal downtime and a strong safety profile.
Sector
Medical Devices
Strategies
Status
Live
Website
neuromark.com
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.